Carlsmed (CARL) reported Q2 2026 revenue of $18.9M, up 57% YoY from $12.1M, driven by growth in its aprevo lumbar platform and ramping contributions from its newer cervical offering. The company attributed the increase to higher procedure volumes. Overall, the update points to improving demand and traction across product lines.
Carlsmed (CARL) reported Q2 2026 revenue of $18.9M, up 57% YoY from $12.1M, driven by growth in its aprevo lumbar platform and ramping contributions from its newer cervical offering. The company attributed the increase to higher procedure volumes. Overall, the update points to improving demand and traction across product lines.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
